GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.

Bengt Nilsson, Per Bümming, Jeanne M. Meis-Kindblom, Anders Odén, Aydin Dortok, Bengt Gustavsson, Katarzyna Sablinska, Lars-Gunnar Kindblom, Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. ,vol. 103, pp. 821- 829 ,(2005) , 10.1002/CNCR.20862

Allan T van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabbeke, Sandra Silberman, Ole S Nielsen, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. ,vol. 358, pp. 1421- 1423 ,(2001) , 10.1016/S0140-6736(01)06535-7

Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461

Rosemarie Mick, John J Crowley, Raymond J Carroll, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Controlled Clinical Trials. ,vol. 21, pp. 343- 359 ,(2000) , 10.1016/S0197-2456(00)00058-1

Martine Van Glabbeke, Jaap Verweij, Ian Judson, Ole Steen Nielsen, EORTC Soft Tissue and Bone Sarcoma Group, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas European Journal of Cancer. ,vol. 38, pp. 543- 549 ,(2002) , 10.1016/S0959-8049(01)00398-7

Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G. Casali, John Zalcberg, Jaap Verweij, Martine Van Glabbeke, Anne Hagemeijer, Ian Judson, KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours European Journal of Cancer. ,vol. 42, pp. 1093- 1103 ,(2006) , 10.1016/J.EJCA.2006.01.030

Christopher L. Corless, Jonathan A. Fletcher, Michael C. Heinrich, Biology of Gastrointestinal Stromal Tumors Journal of Clinical Oncology. ,vol. 22, pp. 3813- 3825 ,(2004) , 10.1200/JCO.2004.05.140

J Verweij, A van Oosterom, J.-Y Blay, I Judson, S Rodenhuis, W van der Graaf, J Radford, A Le Cesne, P.C.W Hogendoorn, E.D di Paola, M Brown, O.S Nielsen, Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. European Journal of Cancer. ,vol. 39, pp. 2006- 2011 ,(2003) , 10.1016/S0959-8049(02)00836-5

M. Debiec-Rychter, H. Dumez, I. Judson, B. Wasag, J. Verweij, M. Brown, S. Dimitrijevic, R. Sciot, M. Stul, H. Vranck, M. Scurr, A. Hagemeijer, M. Van Glabbeke, A.T. van Oosterom, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group European Journal of Cancer. ,vol. 40, pp. 689- 695 ,(2004) , 10.1016/J.EJCA.2003.11.025

John R Zalcberg, Jaap Verweij, Paolo G Casali, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Marcus Schlemmer, Martine Van Glabbeke, Michelle Brown, Ian R Judson, EORTC Soft Tissue and Bone Sarcoma Group, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer. ,vol. 41, pp. 1751- 1757 ,(2005) , 10.1016/J.EJCA.2005.04.034